Robert J Adelman
CIK 1329161 · last filed 2023-09-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AKRO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 595
SAN FRANCISCO, CA 94158
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RayzeBio, Inc. (RYZB) Delisted | 10%+ Owner | 4,910,819 | $62.49 | $306.88M | $0 | 1 | 2023-09-21 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | 10%+ Owner | 2,155,930 | $10.50 | $22.64M | -$6.88M | 1 | 2022-05-17 |
| Metacrine, Inc. (MTCR) Delisted | Director | 2,443,421 | $0.49 | $1.21M | -$1.65M | 2 | 2021-10-26 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 3,033,552 | $54.65 | $165.78M | -$35.50M | 4 | 2020-07-06 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | 3,340,139 | — | — | $3.00M | 3 | 2008-11-18 |
Recent Filings · Page 2 of 2
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-11-09 | ARYx Therapeutics, Inc. (ARYX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.